J Drugs Dermatol. 2022 Aug 1;21(8):854-860. doi: 10.36849/JDD.66791.
The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions. For patients with moderate-to-severe psoriasis seeking amelioration of these symptoms, time to onset of treatment response is an important consideration when determining an appropriate therapeutic approach with their healthcare provider.
In this review, we discuss the fluidity of the definition of rapid response and time-to-response expectations of patients with psoriasis receiving biologic therapies. Next, we focus on time to response of brodalumab, a human anti–interleukin-17 receptor A monoclonal antibody, in patients with moderate-to-severe psoriasis, as measured by the psoriasis area and severity index and the psoriasis symptom inventory. Brodalumab previously exhibited efficacy and safety in treatment of moderate-to-severe psoriasis in three phase 3 trials (AMAGINE-1/-2/-3), warranting further characterization of its ability to meet patient needs regarding rapidity of treatment response. Finally, we place time to response of brodalumab in the context of the current treatment landscape of biologic therapies for psoriasis (particularly those targeting the interleukin-17/interleukin-23 axis).
Direct and indirect comparisons with other interleukin-targeting drugs support brodalumab’s more rapid onset of treatment effects, including skin clearance and relief of itch and pain.
Brodalumab induces a rapid treatment response in patients with moderate-to-severe psoriasis and may promote earlier improvements in quality of life. J Drugs Dermatol. 2022;21(8):854-860. doi:10.36849/JDD.6791.
银屑病对生活质量的影响既来自于身体症状，如疼痛和瘙痒，也来自于病变的高度可见性带来的心理社会影响。对于寻求改善这些症状的中重度银屑病患者，治疗反应的开始时间是与医疗保健提供者确定适当治疗方法时需要考虑的重要因素。
在这篇综述中，我们讨论了快速反应的定义的可变性以及接受生物疗法的银屑病患者对治疗反应时间的期望。接下来，我们重点讨论了中度至重度银屑病患者接受 brodalumab（一种人抗白细胞介素-17 受体 A 单克隆抗体）治疗时的反应时间，其通过银屑病面积和严重程度指数和银屑病症状量表进行评估。brodalumab 在三项 3 期临床试验（AMAGINE-1/-2/-3）中表现出治疗中重度银屑病的疗效和安全性，这进一步证明了其满足患者对治疗反应速度的需求的能力。最后，我们将 brodalumab 的反应时间置于当前生物疗法治疗银屑病的治疗现状（特别是针对白细胞介素-17/白细胞介素-23 轴的疗法）中进行讨论。
与其他靶向白细胞介素的药物的直接和间接比较支持了 brodalumab 更快的治疗效果，包括皮肤清除和瘙痒和疼痛的缓解。
brodalumab 可使中重度银屑病患者迅速获得治疗效果，并可能更早地改善生活质量。J 皮肤病学杂志。2022；21(8):854-860.doi:10.36849/JDD.6791.
